LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of ...
Please provide your email address to receive an email when new articles are posted on . The FDA cleared the use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric ADHD. The ...
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating ...
Monarch, a UK supplier of high-end circular knitting machines, has joined forces with Belgium-based BMSvision to develop and install a new monitoring system for real-time analysis of all production ...
For decades, managing ADHD has meant getting a prescription for Adderall or Ritalin. Now children have another option: the Monarch external Trigeminal Nerve Stimulation (eTNS) system, an ADHD ...
Trial to be conducted at UCLA and funded by a grant from National Institute on Alcohol Abuse and Alcoholism (NIAAA) First phase of trial will enroll up to 30 children ages 8 – 12 with exposure to ...
CHICAGO, April 25, 2017 /PRNewswire/ -- Hill-Rom Holdings, Inc. (NYSE: HRC), a leading global medical technology company, today announced the introduction of the Monarch™ Airway Clearance System.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results